EXSCIENTIA PLC (EXAI) Stock News
NASDAQ:EXAI - Nasdaq - US30223G1022 - ADR - Currency: USD
EXAI Latest News, Press Relases and Analysis
NVIDIA Invested in These 2 AI Stocks, Should You?
Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Mentions: RXRX
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Exscientia (NASDAQ:EXAI) just reported results for the second quarter of 2024.E...
Latest Updates of Viva Biotech's Portfolio Companies
/PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term...
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom
/PRNewswire/ -- USA News Group – Health care is undergoing a tech revolution, with health systems increasingly leveraging artificial intelligence (AI) bots for...
Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Merging with a former rival will bolster its capabilities.
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Merging with a former rival will bolster its capabilities.
Mentions: RXRX
EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024
EXAI stock results show that Exscientia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Exscientia Business Update for Second Quarter and First Half 2024
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger.
Mentions: RXRX
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million in cash and expected synergies of $100 million annually.
Mentions: RXRX
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Operational complementarities expected to yield annual synergies of approximately $100 million
Mentions: RXRX
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
3 Small-Cap Stocks With Explosive 2X Growth Potential
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Exscientia To Contact Him...
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
EXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Exscientia p.l.c. of Class Action Lawsuit and Upcoming Deadlines - EXAI
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Exscientia p.l.c. ("Exscientia" or the "Company") (NASDAQ: EXAI) and...
EXAI DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action - EXAI
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds those who purchased common stock or purchased call options or sold put options,...